Pailan Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pailan Peng has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Shan Lei
School of Basic Medicine Guizhou Medical University Guiyang China
2 shared publicationsShan Tian
Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
2 shared publicationsWanyuan Ruan
Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
2 shared publicationsChengqin Sun
1 shared publicationChujiao Hu
State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University
1 shared publication- Fanghui Zhou
Guizhou Medical University, Guizhou, China
1 shared publication
Latest Publications
- 1 January 2026
- Vol. 42 (1) , 1-11
[GPER1 regulates M2 macrophage polarization through the MYC pathway to influence gastric cancer progression].
Objective G protein-coupled estrogen receptor 1 (GPER1) has been reported to exert tumor-suppressive effects in various malignancies. However, the mechanism by which GPER1 modulates macrophage M2 polarization via the myelocytomatosis oncogene (MYC) signaling pathway and its impact on gastric cancer (GC) progression remains poorly understood. This study aims to explore the role of the GPER1-MYC-interleukin 10 (IL-10) axis in GC. Methods Bioinformatic analyses were conducted to assess GPER1 expression levels and associated signaling pathways. AGS and HGC-27 gastric cancer cell lines with stable GPER1 overexpression or knockdown were generated, using normally cultured cells as controls. Cell proliferation, migration, and invasion were evaluated using the Cell Counting Kit-8 (CCK-8), wound healing, and TranswellTM assays, respectively. Western blotting was performed to examine MYC pathway activation, and the MYC-specific inhibitor 10058-F4 was used for mechanistic validation. A TranswellTM co-culture system was established to simulate tumor-macrophage interactions. Flow cytometry was used to quantify the proportion of M2 macrophages, and IL-10 secretion was measured via ELISA. Results GPER1 expression was significantly downregulated in GC tissues and showed a negative correlation with MYC signaling activity. Knockdown of GPER1 promoted malignant phenotypes in gastric cancer cells, whereas GPER1 overexpression exerted suppressive effects. Mechanistically, GPER1 inhibited M2 macrophage polarization and reduced GC cell proliferation, invasion, and migration by downregulating IL-10 expression via MYC suppression. Notably, the MYC inhibitor reversed the tumor-promoting effects induced by GPER1 knockdown and enhanced the antitumor effects of GPER1 overexpression. Conclusion GPER1 modulates macrophage M2 polarization through the MYC-IL-10 axis, thereby affecting gastric cancer progression. These findings indicate GPER1 as a potential therapeutic target for gastric cancer intervention.
- 1 January 2026
- Vol. 42 (1) , 1-11
[GPER1 regulates M2 macrophage polarization through the MYC pathway to influence gastric cancer progression].
Objective G protein-coupled estrogen receptor 1 (GPER1) has been reported to exert tumor-suppressive effects in various malignancies. However, the mechanism by which GPER1 modulates macrophage M2 polarization via the myelocytomatosis oncogene (MYC) signaling pathway and its impact on gastric cancer (GC) progression remains poorly understood. This study aims to explore the role of the GPER1-MYC-interleukin 10 (IL-10) axis in GC. Methods Bioinformatic analyses were conducted to assess GPER1 expression levels and associated signaling pathways. AGS and HGC-27 gastric cancer cell lines with stable GPER1 overexpression or knockdown were generated, using normally cultured cells as controls. Cell proliferation, migration, and invasion were evaluated using the Cell Counting Kit-8 (CCK-8), wound healing, and TranswellTM assays, respectively. Western blotting was performed to examine MYC pathway activation, and the MYC-specific inhibitor 10058-F4 was used for mechanistic validation. A TranswellTM co-culture system was established to simulate tumor-macrophage interactions. Flow cytometry was used to quantify the proportion of M2 macrophages, and IL-10 secretion was measured via ELISA. Results GPER1 expression was significantly downregulated in GC tissues and showed a negative correlation with MYC signaling activity. Knockdown of GPER1 promoted malignant phenotypes in gastric cancer cells, whereas GPER1 overexpression exerted suppressive effects. Mechanistically, GPER1 inhibited M2 macrophage polarization and reduced GC cell proliferation, invasion, and migration by downregulating IL-10 expression via MYC suppression. Notably, the MYC inhibitor reversed the tumor-promoting effects induced by GPER1 knockdown and enhanced the antitumor effects of GPER1 overexpression. Conclusion GPER1 modulates macrophage M2 polarization through the MYC-IL-10 axis, thereby affecting gastric cancer progression. These findings indicate GPER1 as a potential therapeutic target for gastric cancer intervention.
- Open Access
- 29 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (35) , e44032
Identification of a tumor microenvironment-related gene signature for predicting prognosis in patients with gastric cancer
Tumor microenvironment (TME) plays an important role in the prognosis of gastric cancer (GC). The aim of this study was to identify a TME-related gene signature and provide a basis for prognosis evaluation of GC. X-cell and cluster analyses were performed on 373 tumor samples from The Cancer Genome Atlas-Stomach Adenocarcinoma. Prognostic-related genes were screened using differential analysis. Univariate Cox analysis, LASSO regression, and multivariate Cox analysis were used to determine the candidate genes and construct the prognostic model. Independent prognostic and correlation analyses of clinical characteristics were performed. In the observational study, patients were divided into high- and low-risk groups according to the expression levels and risk coefficients of the 4 model genes. Mutation characteristics, immune cell differences, and TME differences between the high- and low-risk groups were analyzed. The expression levels of these key genes were subsequently validated using reverse transcription quantitative polymerase chain reaction and Western blotting. Two hundred and twenty-five candidate genes were obtained by differential analysis. Performed in the training set, and 4 hub genes (CTHRC1, APOD, S100A12, and ASCL2) were finally determined as prognostic biomarkers. The area under curve of the 1-, 3-, and 5-year receiver operating characteristic curves of the training set, test set, and validation set were all >0.6. There were significant differences in the frequency of some gene mutations and scores (immune score, matrix score, and ESTIMATE composite score) between the high- and low-risk groups. Reverse transcription quantitative polymerase chain reaction and Western blot analyses confirmed that CTHRC1, APOD, and S100A12 were significantly upregulated in the tumor group, whereas ASCL2 expression was significantly downregulated. We developed a TME-related gene signature that can predict the prognosis of patients with GC.
- 29 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (35) , e44032
Open AccessIdentification of a tumor microenvironment-related gene signature for predicting prognosis in patients with gastric cancer
Tumor microenvironment (TME) plays an important role in the prognosis of gastric cancer (GC). The aim of this study was to identify a TME-related gene signature and provide a basis for prognosis evaluation of GC. X-cell and cluster analyses were performed on 373 tumor samples from The Cancer Genome Atlas-Stomach Adenocarcinoma. Prognostic-related genes were screened using differential analysis. Univariate Cox analysis, LASSO regression, and multivariate Cox analysis were used to determine the candidate genes and construct the prognostic model. Independent prognostic and correlation analyses of clinical characteristics were performed. In the observational study, patients were divided into high- and low-risk groups according to the expression levels and risk coefficients of the 4 model genes. Mutation characteristics, immune cell differences, and TME differences between the high- and low-risk groups were analyzed. The expression levels of these key genes were subsequently validated using reverse transcription quantitative polymerase chain reaction and Western blotting. Two hundred and twenty-five candidate genes were obtained by differential analysis. Performed in the training set, and 4 hub genes (CTHRC1, APOD, S100A12, and ASCL2) were finally determined as prognostic biomarkers. The area under curve of the 1-, 3-, and 5-year receiver operating characteristic curves of the training set, test set, and validation set were all >0.6. There were significant differences in the frequency of some gene mutations and scores (immune score, matrix score, and ESTIMATE composite score) between the high- and low-risk groups. Reverse transcription quantitative polymerase chain reaction and Western blot analyses confirmed that CTHRC1, APOD, and S100A12 were significantly upregulated in the tumor group, whereas ASCL2 expression was significantly downregulated. We developed a TME-related gene signature that can predict the prognosis of patients with GC.
- Open Access
- 30 May 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (13) , 1820-1835
An inflammation‐associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma
Inflammation and ferroptosis crosstalk complexly with immune microenvironment of hepatocellular carcinoma (HCC), thus affecting the efficacy of immunotherapy. Herein, our aim was to identify the inflammation‐associated ferroptosis (IAF) biomarkers for contributing HCC. A total of 224 intersecting DEGs identified from different inflammation‐ and ferroptosis‐subtypes were set as IAF genes. Seven of them including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 were used for construction of a risk model which classified HCC patients into two groups (high and low risk). HCC patients in the high‐risk group exhibited shorter survival rate and higher immune score, and were predicted to have higher respond rate in immune checkpoint inhibition (ICI) therapy. Levels of the seven genes were significantly changed in HCC tissues in comparison to adjacent tissues. After inserting the gene expression into the risk model, we found that the risk model exhibited the higher diagnostic value for distinguish HCC tissues compared each single gene. Furthermore, HCC tissues from our research group with high‐risk score exhibited more cases of microsatellite instability (MSI), heavier tumour mutational burden (TMB), higher expression level of PDL1 and cells with CD8. Knockdown of APOA5 reduced HCC cell proliferation combining with elevating inflammation and ferroptosis levels. In conclusion, we considered APOA5 maybe a novel target for suppressing HCC via simultaneously elevating inflammation and ferroptosis levels, and signature constructed by seven IAF genes including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 can act as a biomarker for optimising the diagnosis, prognosis evaluation and immunotherapy options in HCC patients.
- 30 May 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (13) , 1820-1835
Open AccessAn inflammation‐associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma
Inflammation and ferroptosis crosstalk complexly with immune microenvironment of hepatocellular carcinoma (HCC), thus affecting the efficacy of immunotherapy. Herein, our aim was to identify the inflammation‐associated ferroptosis (IAF) biomarkers for contributing HCC. A total of 224 intersecting DEGs identified from different inflammation‐ and ferroptosis‐subtypes were set as IAF genes. Seven of them including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 were used for construction of a risk model which classified HCC patients into two groups (high and low risk). HCC patients in the high‐risk group exhibited shorter survival rate and higher immune score, and were predicted to have higher respond rate in immune checkpoint inhibition (ICI) therapy. Levels of the seven genes were significantly changed in HCC tissues in comparison to adjacent tissues. After inserting the gene expression into the risk model, we found that the risk model exhibited the higher diagnostic value for distinguish HCC tissues compared each single gene. Furthermore, HCC tissues from our research group with high‐risk score exhibited more cases of microsatellite instability (MSI), heavier tumour mutational burden (TMB), higher expression level of PDL1 and cells with CD8. Knockdown of APOA5 reduced HCC cell proliferation combining with elevating inflammation and ferroptosis levels. In conclusion, we considered APOA5 maybe a novel target for suppressing HCC via simultaneously elevating inflammation and ferroptosis levels, and signature constructed by seven IAF genes including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 can act as a biomarker for optimising the diagnosis, prognosis evaluation and immunotherapy options in HCC patients.
- Open Access
- 1 December 2022
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 9, 1415-1431
The Clinical Relevance and Immune Correlation of SLC10 Family Genes in Liver Cancer
Background and Aim: This study was aimed to reveal the clinical relevance and immune correlation of the SLC10 family genes in liver cancer. Methods: A comprehensive bioinformatics analysis was utilized to determine the gene expression, genetic alterations, DNA methylation, clinical significance, survival association and immune correlation of seven SLC10 family genes in liver cancer. The multiplexed immunohistochemical technique was applied to determine the association between SLC10A3 protein expression and immune cells, and the correlation between SLC10A3 protein and immune checkpoints (PD1 and PD-L1) in a cohort of 32 individuals with liver cancer. Results: The expression of SLC10 family genes was different between normal liver tissues and malignant liver tissues. SLC10A5 showed the highest alteration rate (8%), followed by SLC10A3 (2.8%). Low expression of SLC10A1 was indicative of poor tumor grade and advanced tumor stage in liver cancer. Scatter plots uncovered that expression of SLC10A3 was inversely associated with SLC10A1 and SLC10A5 expression in liver cancer. The expression of SLC10A1 and SLC10A5 was strongly associated with their DNA methylation. SLC10A1 expression was a reliable genetic biomarker for the prediction of survival outcomes in liver cancer population. Expression of SLC10 family genes was remarkably linked with the abundance of most immune infiltrating cells in liver cancer, and SLC10A3 was the most significant member. The multiplexed immunohistochemical technique confirmed that there existed the significant correlations between SLC10A3 protein expression and CD4 T cells, CD20 B cells and the close association with PD-1 in the stromal area from malignant tissues. Conclusion: The expressions of SLC10 family genes were different between normal liver tissues and malignant liver tissues, and they were correlated with each other in liver cancer. SLC10A1 possesses the most significant correlation with survival outcomes. SLC10A3 exhibited the most significant relationship with immune cells, as revealed by bioinformatics analysis and multispectral imaging technique.
- 1 December 2022
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 9, 1415-1431
Open AccessThe Clinical Relevance and Immune Correlation of SLC10 Family Genes in Liver Cancer
Background and Aim: This study was aimed to reveal the clinical relevance and immune correlation of the SLC10 family genes in liver cancer. Methods: A comprehensive bioinformatics analysis was utilized to determine the gene expression, genetic alterations, DNA methylation, clinical significance, survival association and immune correlation of seven SLC10 family genes in liver cancer. The multiplexed immunohistochemical technique was applied to determine the association between SLC10A3 protein expression and immune cells, and the correlation between SLC10A3 protein and immune checkpoints (PD1 and PD-L1) in a cohort of 32 individuals with liver cancer. Results: The expression of SLC10 family genes was different between normal liver tissues and malignant liver tissues. SLC10A5 showed the highest alteration rate (8%), followed by SLC10A3 (2.8%). Low expression of SLC10A1 was indicative of poor tumor grade and advanced tumor stage in liver cancer. Scatter plots uncovered that expression of SLC10A3 was inversely associated with SLC10A1 and SLC10A5 expression in liver cancer. The expression of SLC10A1 and SLC10A5 was strongly associated with their DNA methylation. SLC10A1 expression was a reliable genetic biomarker for the prediction of survival outcomes in liver cancer population. Expression of SLC10 family genes was remarkably linked with the abundance of most immune infiltrating cells in liver cancer, and SLC10A3 was the most significant member. The multiplexed immunohistochemical technique confirmed that there existed the significant correlations between SLC10A3 protein expression and CD4 T cells, CD20 B cells and the close association with PD-1 in the stromal area from malignant tissues. Conclusion: The expressions of SLC10 family genes were different between normal liver tissues and malignant liver tissues, and they were correlated with each other in liver cancer. SLC10A1 possesses the most significant correlation with survival outcomes. SLC10A3 exhibited the most significant relationship with immune cells, as revealed by bioinformatics analysis and multispectral imaging technique.
- Open Access
- 9 September 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1001381
A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) were used to obtain RNA sequencing data and clinical characteristics of glioma tissues, while the stromal and immune scores of TCGA glioma tissues were determined using the ESTIMATE algorithm. Differentially expressed genes (DEGs), the protein–protein interaction(PPI) network, and least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were used to select hub genes associated with stroma and immune scores and the prognoses of patients and to construct the risk model. The practicability and specificity of the risk model in both IDH1mt and IDH1-wildtype (wtIDH1) gliomas in TCGA and CGGA were evaluated. Molecular mechanisms, immunological characteristics and benefits of immune checkpoint blockade therapy in glioma tissues with IDH1mt were analyzed using GSEA, immunohistochemical staining, CIBERSORT, and T-cell dysfunction and exclusion (TIDE) analysis. The overall survival rate for IDH1mt-glioma patients with high stroma/immune scores was lower than that for those with low stroma/immune scores. A total of 222 DEGs were identified in IDH1mt glioma tissues with high stroma/immune scores. Among them, 72 genes had interactions in the PPI network, while three genes, HLA-DQA2, HOXA3, and SAA2, were selected as hub genes and used to construct risk models classifying patients into high- and low-risk score groups, followed by LASSO and Cox regression analyses. This risk model showed prognostic value in IDH1mt glioma in both TCGA and CCGA; nevertheless, the model was not suitable for wtIDH1 glioma. The risk model may act as an independent prognostic factor for IDH1mt glioma. IDH1mt glioma tissues from patients with high-risk scores showed more infiltration of M1 and CD8 T cells than those from patients with low-risk scores. Moreover, TIDE analysis showed that immune checkpoint blockade(ICB) therapy was highly beneficial for IDH1mt patients with high-risk scores. The risk model showed specific potential to predict the prognosis of IDH1mt-glioma patients, as well as guide ICB, contributing to the diagnosis and therapy of IDH1mt-glioma patients.
- 9 September 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1001381
Open AccessA specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) were used to obtain RNA sequencing data and clinical characteristics of glioma tissues, while the stromal and immune scores of TCGA glioma tissues were determined using the ESTIMATE algorithm. Differentially expressed genes (DEGs), the protein–protein interaction(PPI) network, and least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were used to select hub genes associated with stroma and immune scores and the prognoses of patients and to construct the risk model. The practicability and specificity of the risk model in both IDH1mt and IDH1-wildtype (wtIDH1) gliomas in TCGA and CGGA were evaluated. Molecular mechanisms, immunological characteristics and benefits of immune checkpoint blockade therapy in glioma tissues with IDH1mt were analyzed using GSEA, immunohistochemical staining, CIBERSORT, and T-cell dysfunction and exclusion (TIDE) analysis. The overall survival rate for IDH1mt-glioma patients with high stroma/immune scores was lower than that for those with low stroma/immune scores. A total of 222 DEGs were identified in IDH1mt glioma tissues with high stroma/immune scores. Among them, 72 genes had interactions in the PPI network, while three genes, HLA-DQA2, HOXA3, and SAA2, were selected as hub genes and used to construct risk models classifying patients into high- and low-risk score groups, followed by LASSO and Cox regression analyses. This risk model showed prognostic value in IDH1mt glioma in both TCGA and CCGA; nevertheless, the model was not suitable for wtIDH1 glioma. The risk model may act as an independent prognostic factor for IDH1mt glioma. IDH1mt glioma tissues from patients with high-risk scores showed more infiltration of M1 and CD8 T cells than those from patients with low-risk scores. Moreover, TIDE analysis showed that immune checkpoint blockade(ICB) therapy was highly beneficial for IDH1mt patients with high-risk scores. The risk model showed specific potential to predict the prognosis of IDH1mt-glioma patients, as well as guide ICB, contributing to the diagnosis and therapy of IDH1mt-glioma patients.
- Open Access
- 30 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis
Aim: The Gustave Roussy Immune Score (GRIm-Score) was originally designed to select cancer patients for immunotherapy, and later was reported to be a novel prognostic scoring system in lung cancer and esophageal cancer. This study was aimed to determine the prognostic role and predictive performance of GRIm-Score in colorectal cancer (CRC) CRC patients. Methods: We conducted a single-institution study of 1,579 adult CRC patients receiving surgical removal, and those patients were divided into low GRIm-Score group (scores 0, 1) and high GRIm-Score group (scores 2, 3). Propensity score matching (PSM) was executed to balance the potential confounding factors between the two groups. Survival and time-dependent receiver operating characteristic (Td-ROC) analyses were applied to depict the prognostic role and predictive significance of GRIm-Score in CRC patients. Results: There were 200 cases CRC patients in high GRIm-Score group and 1,379 cases in low GRIm-Score group. CRC patients with high GRIm-Score correspond with higher level of CEA, CA125, and inflammatory indexes, such as NLR, PLR, SII, PNI, and ALRI. Correlation analysis exhibited that GRIm-Score correlated well with the established inflammatory indexes. Survival analysis revealed that CRC patients in high GRIm-Score group showed worse overall survival (OS, P Conclusion: GRIm-Score, a novel inflammatory and nutritional risk scoring system, is a potent prognostic index in CRC patients receiving surgical removal. GRIm-Score can be used as an effective and simplified risk stratification tool for postoperative survival prediction of CRC patients.
- 30 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessGustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis
Aim: The Gustave Roussy Immune Score (GRIm-Score) was originally designed to select cancer patients for immunotherapy, and later was reported to be a novel prognostic scoring system in lung cancer and esophageal cancer. This study was aimed to determine the prognostic role and predictive performance of GRIm-Score in colorectal cancer (CRC) CRC patients. Methods: We conducted a single-institution study of 1,579 adult CRC patients receiving surgical removal, and those patients were divided into low GRIm-Score group (scores 0, 1) and high GRIm-Score group (scores 2, 3). Propensity score matching (PSM) was executed to balance the potential confounding factors between the two groups. Survival and time-dependent receiver operating characteristic (Td-ROC) analyses were applied to depict the prognostic role and predictive significance of GRIm-Score in CRC patients. Results: There were 200 cases CRC patients in high GRIm-Score group and 1,379 cases in low GRIm-Score group. CRC patients with high GRIm-Score correspond with higher level of CEA, CA125, and inflammatory indexes, such as NLR, PLR, SII, PNI, and ALRI. Correlation analysis exhibited that GRIm-Score correlated well with the established inflammatory indexes. Survival analysis revealed that CRC patients in high GRIm-Score group showed worse overall survival (OS, P Conclusion: GRIm-Score, a novel inflammatory and nutritional risk scoring system, is a potent prognostic index in CRC patients receiving surgical removal. GRIm-Score can be used as an effective and simplified risk stratification tool for postoperative survival prediction of CRC patients.